

To: Brian Doll (E-mail) <brian.e.doll@exxonmobil.com>; Bruce M. Jarnot (E-mail) <jarnotb@api.org>; Burnett, Don (E-mail) <burnetdm@bp.com>; Michael Johnston (E-mail) <Mike.d.Johnston@ConocoPhillips.com>; Russell White (E-mail) <whiter@api.org>; Stuart Cagen (E-mail) </O=SHELL/OU=MSXSCC/CN=RECIPIENTS/CN=SC724012>; Zach Wong (E-mail) <ZachWong@chevrontexaco.com>; Anita Balaraman (E-mail) <anita.balaraman@chevrontexaco.com>; Jennifer Galvin (E-mail) <jennifer.b.galvin@conocophillips.com>; Matthew A Hughes (E-mail) <hughm7@BP.com>; Michael Bird (E-mail) <michael.g.bird@exxonmobil.com>; Shan Tsai (E-mail) </O=SHELL/OU=MSXSOC/cn=Recipients/cn=ST196949>; Stephen Bowes (E-mail) <stephen.m.bowes@exxonmobil.com>; Alex Yelland (E-mail) <alex.yelland@chevron.com>; Myron Harrison (E-mail) <myron.c.harrison@exxonmobil.com>; Richard Herold (E-mail) <heroldra@bp.com>; Trisha Perkins (E-mail) <trisha.m.perkins@exxonmobil.com>; John Wagner (E-mail) <wagner@api.org>; Mark Fitzsimmons (E-mail) <mfitzsim@steptoe.com>

From: Clegg, Patsy M SCC-DCS/22 </O=SHELL/OU=MSXSCC/CN=RECIPIENTS/CN=PH197432>

Cc:

Bcc:

Received Date: 2007-02-14 17:17:18 GMT

Subject: BHRC draft letter to Irons for review and response by cob Feb 14

Regards,
Patsy

Patsy Clegg
Product Steward, HSSE
Shell Chemical LP
One Shell Plaza, 910 Louisiana, Houston, TX 77002-4916

Tel: +1 713 241 2521 **Fax:** 3325
Email: patsy.clegg@shell.com
Internet: <http://www.shell.com/chemicals>

Business Success through HSSE Excellence

Attachments:

API_ Alternative Ltr to RIrons re Shanghai Health Study (2).ZIP

DRAFT

February _____, 2007

Via U.S. MAIL

Richard Irons, PhD, DABT
Principal Investigator, Shanghai Health Study
University of Colorado Health Sciences Center
4200 East 9th Avenue, C238
Denver, CO 80262

Re: ***Supplemental Funding for Shanghai Health Study***

Dear Dr. Irons:

I am writing on behalf of the Benzene Health Research Consortium (“BHRC”), the group of companies supporting the scientific and clinical research you are conducting in China, Shanghai Health Study. We appreciate your serving as a principal investigator for this unique project in Shanghai. We have considered your request for additional support, and are pleased to report that we are prepared to offer additional funding, in the amount of \$6,559,864. It will be necessary to have agreements executed and in place before the actual commitment is finalized and disbursement of funds begins. **[CORRECT AMOUNT?]**

We assume the substantive provisions of our original agreement will be a part of subsequent contracts necessary to enable completion of the study. We are also providing separate and additional funding for QA/QC, as was outlined in your original proposal. As you have suggested, Dr. Jerry Rice, chair of the Scientific Review Panel for the study, as well as other colleagues, have agreed to assist in this effort. We assume the supplemental QA/QC plan, as developed by you and the Data Process Quality Assurance team, whose charter is attached, will be implemented. Please contact us if either of our assumptions is not correct.

We would also appreciate receiving your contract proposal, as well as agreements with the University of Colorado and Fudan University. Please forward at your earliest convenience. We know the additional funding is time-sensitive, and we will do what we can to expedite it.

Sincerely yours,

Jennifer B. Galvin, Ph.D., DABT, CIH
Chair, Technical Committee
Shanghai Health Study

To: 'Galvin, Jennifer B' <Jennifer.B.Galvin@conocophillips.com>; White, R AMERTRA-WAT <RAY@AMERTRANS.DEMON.CO.UK>
From: Clegg, Patsy M SCC-DCS/22
</O=SHELL/OU=MSXSCC/CN=RECIPIENTS/CN=PH197432>
Cc: mfitzsim@steptoe.com <mfitzsim@steptoe.com>
Bcc:
Received Date: 2007-02-20 20:04:43 GMT
Subject: RE: BHRC Letter to Dr Irons

The final version as I recorded it in our call. have not received any suggested changes.

Regards,
Patsy

Patsy Clegg
Product Steward, HSSE
Shell Chemical LP
One Shell Plaza, 910 Louisiana, Houston, TX 77002-4916

Tel: +1 713 241 2521 Fax: 3325
Email: patsy.clegg@shell.com
Internet: <http://www.shell.com/chemicals>

Business Success through HSSE Excellence

-----Original Message-----

From: Galvin, Jennifer B [mailto:Jennifer.B.Galvin@conocophillips.com]
Sent: Tuesday, February 20, 2007 1:56 PM
To: Clegg, Patsy M SCC-DCS/22
Cc: mfitzsim@steptoe.com
Subject: Re: BHRC Letter to Dr Irons

Any changes to the letter??

Who had the FINAL version?

Please send to Russ White. My blackberry will not forward attachments.

Thanks

Thanks,
Jennifer Galvin
918-661-3865
918-662-1139 (fax)
918-519-6302 (cell)

Sent from my BlackBerry Wireless Handheld

-----Original Message-----

From: patsy.clegg@shell.com <patsy.clegg@shell.com>
To: Galvin, Jennifer B
CC: brian.e.doll@exxonmobil.com <brian.e.doll@exxonmobil.com>; jarnotb@api.org <jarnotb@api.org>; burnetdm@bp.com <burnetdm@bp.com>; Johnston, Michael D.; whiter@api.org <whiter@api.org>; stuart.cagen@shell.com <stuart.cagen@shell.com>; ZachWong@chevrontexaco.com

<ZachWong@chevrontexaco.com>; anita.balaraman@chevrontexaco.com
<anita.balaraman@chevrontexaco.com>; Galvin, Jennifer B; hughm7@bp.com <hughm7@bp.com>;
michael.g.bird@exxonmobil.com <michael.g.bird@exxonmobil.com>; Shan.Tsai@shell.com
<Shan.Tsai@shell.com>; stephen.m.bowes@exxonmobil.com <stephen.m.bowes@exxonmobil.com>;
alex.yelland@chevron.com <alex.yelland@chevron.com>; myron.c.harrison@exxonmobil.com
<myron.c.harrison@exxonmobil.com>; heroldra@bp.com <heroldra@bp.com>;
trisha.m.perkins@exxonmobil.com <trisha.m.perkins@exxonmobil.com>
Sent: Tue Feb 20 09:34:59 2007
Subject: BHRC Letter to Dr Irons

Jennifer;

Please email letter to Dr. Irons. Work with API to get a hard copy in overnight mail.

Patsy Clegg
Product Steward
Shell Chemical LP
One Shell Plaza, 910 Louisiana, Houston, TX 77002-4916

Tel: +1 713 241 2521 Fax: 3325
Email: patsy.clegg@shell.com
Internet: <http://www.shell.com/chemicals>

Attachments:

API_ Alternative Ltr to Rlrons re Shanghai Health Study- Final.ZIP

DRAFT

February _____, 2007

Via U.S. MAIL

Richard Irons, PhD, DABT
Principal Investigator, Shanghai Health Study
University of Colorado Health Sciences Center
4200 East 9th Avenue, C238
Denver, CO 80262

Re: *Supplemental Funding for Shanghai Health Study*

Dear Dr. Irons:

I am writing on behalf of the Benzene Health Research Consortium (“BHRC”), the group of companies supporting the scientific and clinical research you are conducting in China, Shanghai Health Study. We appreciate your serving as a principal investigator for this unique project in Shanghai. We have considered your request for additional support, and are pleased to report that we are prepared to offer additional funding, in the amount of \$6,559,864. It will be necessary to have agreements executed and in place before the actual commitment is finalized and disbursement of funds begins.

We assume the substantive provisions of our original agreement will be a part of subsequent contracts necessary to enable completion of the study. We are also providing separate and additional funding for QA/QC, as was outlined in your original proposal. As you have suggested, Dr. Jerry Rice, chair of the Scientific Review Panel for the study, as well as other colleagues, have agreed to assist in this effort. We assume the supplemental QA/QC plan, as developed by you and the Data Process Quality Assurance team, whose charter is attached, will be implemented. Please contact us if either of our assumptions is not correct.

We would also appreciate receiving your contract proposal, as well as agreements with the University of Colorado and Fudan University. Please forward at your earliest convenience. We know the additional funding is time-sensitive, and we will do what we can to expedite it.

Sincerely yours,

Jennifer B. Galvin, Ph.D., DABT, CIH
Chair, Technical Committee
Shanghai Health Study